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INTRODUCTION
Dilation and curettage (D&C) can cause various 
complications. Bleeding is one of its most common 
complications (1, 2). Post-abortion hemorrhage in the 
second trimester accounts for 33% of cases of abortion-
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Objective: To evaluate the safety and efficacy of prophylactic uterine artery embolization (UAE) before obstetrical 
procedures with high risk for massive bleeding.
Materials and Methods: A retrospective review of 29 female patients who underwent prophylactic UAE from June 2009 to 
February 2014 was performed. Indications for prophylactic UAE were as follows: dilatation and curettage (D&C) associated 
with ectopic pregnancy (cesarean scar pregnancy, n = 9; cervical pregnancy, n = 6), termination of pregnancy with abnormal 
placentation (placenta previa, n = 8), D&C for retained placenta with vascularity (n = 5), and D&C for suspected gestational 
trophoblastic disease (n = 1). Their medical records were reviewed to evaluate the safety and efficacy of UAE.
Results: All women received successful bilateral prophylactic UAE followed by D&C with preservation of the uterus. In all 
patients, UAE followed by obstetrical procedure prevented significant vaginal bleeding on gynecologic examination. There 
was no major complication related to UAE. Vaginal spotting continued for 3 months in three cases. Although oligomenorrhea 
continued for six months in one patient, normal menstruation resumed in all patients afterwards. During follow-up, four 
had subsequent successful natural pregnancies. Spontaneous abortion occurred in one of them during the first trimester. 
Conclusion: Prophylactic UAE before an obstetrical procedure in patients with high risk of bleeding or symptomatic 
bleeding may be a safe and effective way to manage or prevent serious bleeding, especially for women who wish to 
preserve their fertility.
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related mortality (3). Bleeding can lead to maternal 
mortality, especially in high-risk patients with abnormal 
placentation such as placenta previa and ectopic pregnancy, 
including cesarean scar pregnancy (CSP) (4, 5).
Uterine artery embolization (UAE) is an efficacious 
treatment approach for postpartum hemorrhage. It has 
been recently indicated for post-abortion hemorrhage (3, 
6). Some reports have suggested that UAE can successfully 
treat bleeding following D&C in high-risk patients, 
including those with CSP or abnormal placentation (4-
6). Furthermore, prophylactic UAE has been introduced to 
decrease intraoperative blood loss in patients at high risk 
of peripartum hemorrhage (7).
However, few reports are available on the use of 
prophylactic embolization before obstetric procedures, 
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Institutional Review Board. The requirement for informed 
consent was waived due to its retrospective nature. 
This study included 29 female patients who underwent 
prophylactic UAE between June 2009 and February 2014 
before undergoing obstetric procedures, including D&C 
and delivery for termination of pregnancy and procedures 
commonly associated with massive bleeding. Characteristics 
of patients are summarized in Table 1. Indications for 
prophylactic UAE were as follows: D&C associated with 
ectopic pregnancy (CSP, n = 9; cervical pregnancy, n = 
6), termination of pregnancy with abnormal placentation 
including therapeutic abortion in high-risk patients with 
life-threatening vaginal bleeding or expected severe 
bleeding after an obstetric procedure. The objective of 
this study was to determine the safety and efficacy of 
prophylactic UAE in obstetric procedures for preventing 
hemorrhage in high-risk patients.
MATERIALS AND METHODS
Patients
This retrospective single-center study was approved by our 
Table 1. Patients’ Characteristics and Clinical Outcomes (n = 29)
No./Age/
Parity
GA  
(Weeks)
Obstetric 
Procedure
Indication for  
Obstetric Procedure
Indication for UAE
Vaginal 
Bleeding
Interval* 
(Days)
Hemoglobin  
(g/dL) (Pre/Post)
1/37/m 4.1 D&C Post-abortive bleeding Retained placenta with vascularity + 0 12.3/12.2
2/35/m 8.3 D&C Ectopic pregnancy CSP + 0 7.2/9.6†
3/33/n 26.4 Hysterotomy Fetal abnormality Placenta previa - 0 12.3/10.5
4/35/m 39.7 D&C Postpartum bleeding Retained placenta with vascularity + 0 13.3/12.1
5/35/m 6.7 D&C Ectopic pregnancy Cervical pregnancy + 0 12.9/12.2
6/32/n 11.3 D&C Ectopic pregnancy Cervical pregnancy + 1 13.4/11.7
7/45/m 5.7 D&C Ectopic pregnancy CSP - 0 12.8/11.5
8/32/m 6.9 D&C Ectopic pregnancy CSP + 0 13.6/12.4
9/28/m 22.7 Delivery Fetal abnormality Placenta previa - 1 9.4/9.6
10/36/m 12.9 D&C Fetal abnormality Placenta previa - 1 10.7/9.1
11/32/m 6.9 D&C Ectopic pregnancy CSP + 0 12.9/11.9
12/26/n 22.1 Delivery Fetal abnormality Placenta previa + 3 8.5/7.1
13/36/m 16.7 Delivery Fetal abnormality Placenta previa - 2 12.1/11.5
14/30/m 19.4 Delivery Fetal abnormality Placenta previa + 1 10.3/9.8
15/34/m 7.9 HSS removal Post-abortive bleeding Retained placenta with vascularity + 4 13.3/11.1
16/46/m 6.0 D&C Ectopic pregnancy CSP + 1 10.8/8.2
17/35/m 9.1 D&C Ectopic pregnancy Cervical pregnancy + 0 11.5/11
18/26/m 7.7 D&C Ectopic pregnancy CSP + 0 12.9/12.5
19/26/m 15.7 Delivery Fetal abnormality Placenta previa - 1 11.9/12.5
20/34/m 22.9 Delivery Fetal abnormality Placenta previa - 0 7.9/9.1
21/36/m 9.6 D&C Ectopic pregnancy CSP + 0 13/12
22/23/n 6.7 D&C Post-abortive bleeding Retained placenta with vascularity + 0 12.7/12
23/37/m 5.4 D&C Ectopic pregnancy Cervical pregnancy + 0 5.8/9.2†
24/30/m 8.4 D&C Ectopic pregnancy CSP - 1 12.4/10.5
25/36/m 7.0 D&C Ectopic pregnancy Cervical pregnancy + 0 10.5/9.9
26/25/m 5.4 D&C Ectopic pregnancy CSP + 0 13.9/12.5
27/34/m 5.0 D&C GTD GTD + 0 10.2/11
28/44/m 14.1 D&C Post-abortive bleeding Retained placenta with vascularity + 1 10.2/11.5
29/46/m 8.9 D&C Ectopic pregnancy Cervical pregnancy + 0 8.3/11.1
33.9 ± 6.0 12.1 ± 8.2 0.6 ± 1.0
11.3 ± 2.1/ 
10.9 ± 1.4
*Interval from UAE to abortion, †Transfusion was performed. CSP = cesarean scar pregnancy, D&C = dilation and curettage, GA = 
gestational age, GTD = gestational trophoblastic disease, HSS = hysterosalpingoscopy, m = multiparous, n = nulliparous, UAE = uterine 
artery embolization
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(placenta previa, n = 8), D&C for retained placenta with 
vascularity (n = 5), and D&C for suspected gestational 
trophoblastic disease (GTD; n = 1). One patient (Patient 4) 
had symptomatic vaginal bleeding after full-term delivery. 
She underwent D&C for treatment of retained placenta after 
prophylactic embolization. A multiparous patient (Patient 
10) was diagnosed to have a fetal death with placenta 
previa at the beginning of the second trimester. Even 
though she had no symptomatic bleeding, the obstetrician 
decided to perform prophylactic UAE at the request of the 
patient due to her painful memory of postpartum bleeding 
in a previous pregnancy. Symptomatic vaginal bleeding was 
present in 21 patients before UAE.
The mean age of patients was 33.9 ± 6.0 years. Of these 
patients, 25 (86.2%) were multiparous and four (13.8%) 
were nulliparous. The mean gestational age was 12.1 ± 8.2 
weeks. During hospital stay, conservative treatments were 
administered to all patients. Transfusion was performed 
depending on clinical situation.
Embolization Procedure
After puncturing the common femoral artery, a 5 Fr 
vascular sheath was inserted. Uterine arteries and other 
potential bleeding focuses were evaluated by selective 
bilateral internal iliac arteriogram. A cobra catheter 
(Radifocus; Terumo Medical Corp., Tokyo, Japan) and 0.035-
in guidewire were used to obtain access to the contralateral 
internal iliac artery. Waldman loop technique was used 
for selecting the ipsilateral internal iliac artery with the 
same catheter. A microcatheter (Progreat; Terumo Medical 
Corp.) was used to select the uterine artery according to a 
roadmap image. Bilateral UAE at the proximal portion of the 
uterine artery with gelatin sponge particles was performed 
after artery selection. After UAE, complete occlusion of the 
target vessel was confirmed by angiography. Pain control 
during and after UAE was performed conservatively. UAE 
was performed in our angiographic suite by interventional 
radiologists with 5 to 25 years of experience.
Follow-Up
Technical success was defined as successful catheterization 
and embolization of the target culprit arteries that resulted 
in hemostasis at the final angiography. Clinical success was 
defined as the termination of bleeding after the initial UAE 
without needing additional UAE or surgery for hemostasis 
after D&C. We obtained data on baseline characteristics, 
treatment before embolization, hemoglobin levels before/
after UAE, required transfusions, embolization technique 
details, and clinical follow-up through careful review of 
obstetric medical records of patients. We also reviewed 
their medical records at follow-up visits 1 and 3 months 
after discharge to obtain data on their menstrual cycles or 
pregnancies after UAE and subsequent D&C.
RESULTS
The outcomes of the 29 patients are summarized in 
Table 1. The technical success rate was 100%. Complete 
embolization of bilateral uterine arteries on pelvic 
angiography was achieved for all included patients. No 
bleeding problem occurred. Transfusion or hysterectomy 
was not required during or after the obstetric procedures. 
The estimated amount of blood loss during the obstetric 
procedure was < 500 mL in all patients. No procedure-
related complications occurred after UAE. One patient 
(Patient 6) clinically showed chorioamnionitis after 
the abortive delivery. Fetal death was suspected. After 
conservative treatment, the patient fully recovered.
The following obstetric procedures were used: D&C 
(n = 21), delivery (n = 6), hysterotomy (n = 1), and 
hysterosalpingoscopic removal of remnant placenta (n = 1). 
Therapeutic abortion with delivery (n = 6) was performed 
in cases of fetal death due to known fatal fetal anomaly. 
Two patients (Patients 3 and 15) underwent hysterotomy 
or hysterosalpingoscopic removal under general anesthesia. 
The remaining 27 patients underwent obstetrical procedures 
under local anesthesia without conscious sedation. The 
mean interval between UAE and the obstetric procedure was 
0.6 ± 1.0 days. The obstetric procedure was performed on 
the same day as UAE in 18 patients. The mean hospital stay 
duration after the obstetric procedure was 1.9 ± 2.1 days 
(range, 1–9 days). The mean hemoglobin levels before and 
after UAE were 11.3 ± 2.1 and 10.9 ± 1.4 g/dL, respectively. 
Before the procedure was performed, transfusion of blood 
product at emergency unit was conducted for two patients 
(Patients 2 and 23). Both patients had severe anemia with 
hemoglobin levels of 7.2 and 5.8 g/dL, respectively. After 
transfusion, UAE and subsequent D&C were performed 
successfully.
The angiographic findings included diffuse uterine 
enhancement (n = 27) and mass-like enhancement (n = 2, 
Patients 1 and 21) (Fig. 1). In three patients (Patients 9, 
12, and 20), the bony structure of the fetus was visible due 
to advanced gestational age. No pseudoaneurysm or active 
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contrast extravasation was found. To increase the possibility 
of future pregnancy, all women underwent bilateral 
embolization by using gelatin sponge particles rather than 
polyvinyl alcohol (Figs. 2, 3). No arteries other than uterine 
arteries were embolized.
All patients underwent routine follow-up in an outpatient 
clinic after discharge. Successful hemostasis with minimal 
post procedural vaginal bleeding was confirmed after 
UAE. In three cases (Patients 7, 8, and 15), vaginal 
spotting continued for 3 months. Although oligomenorrhea 
continued for 6 months in one patient (Patient 10), normal 
menstruation resumed in all other patients. Four patients 
(Patients 15, 18, 19, and 21) had successful natural 
pregnancies during follow-up. Two patients (Patients 18 and 
21) had normal cesarean delivery. One patient (Patient 19) 
had vaginal delivery. One (Patient 15) had a spontaneous 
abortion during the first trimester.
DISCUSSION
In the present study, we used prophylactic UAE to manage 
symptomatic vaginal bleeding or control the high risk of 
vaginal bleeding during obstetric procedures. We found that 
patients with high-risk of symptomatic vaginal bleeding 
who were treated with UAE followed by an obstetric 
procedure experienced no serious bleeding complication. No 
severe side effects related to UAE were observed. Our study 
indicated that prophylactic UAE followed by an obstetric 
Fig. 1. Placenta previa. 
A, B. Angiograms of left (A) and right uterine arteries (B) showing diffuse contrast staining (arrows), suggesting placenta on lower uterine 
body. Fetus (arrowheads) was confirmed to be dead based on ultrasonography. C. Post-embolization angiogram after contrast injection from right 
internal iliac artery showing devascularized placenta and contrast stasis (arrows) suggesting complete embolization.
A B C
Fig. 2. Cervical pregnancy. 
A. Transabdominal ultrasonographic image showing gestational sac (arrows) in uterine cervix. Fetus (arrowhead) can also be seen. B. Late arterial 
angiogram showing engorged uterine artery and contrast staining at uterine cervix. C. Fluoroscopic image after embolization showing contrast 
stasis due to embolized gel foam in right uterine artery.
A B C
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procedure might be an effective treatment for patients at 
high risk of bleeding. Our results also suggested that UAE 
followed by an obstetric procedure did not increase the risk 
of side effects. We assessed four categories as indications 
for prophylactic UAE. One category (n = 15) comprised 
ectopic pregnancies such as cervical pregnancy and CSP 
that could cause serious bleeding after abortion (usually in 
the first trimester). The second category (n = 8) included 
abnormal placentation such as placenta previa, accreta, and 
percreta that could cause serious bleeding. All patients in 
this category had fetal death or serious fetal anomaly and 
needed therapeutic abortion. The third category (n = 5) had 
retained placental tissue that could cause active bleeding 
after delivery or previous abortion. Before repeating D&C 
to treat retained tissue that caused active bleeding, 
prophylactic UAE was performed to prevent massive 
bleeding during the repeated D&C. The final category (n = 1) 
was GTD with active bleeding.
Although induced abortion has low morbidity and 
mortality, hemorrhage is the most common serious 
complication. Hemorrhage is defined as an estimated blood 
loss volume of > 500 mL or bleeding requiring a transfusion. 
It occurs in approximately 0.82 cases per 100000 abortions 
(6, 8). When initial conservative methods fail, hemorrhage 
can lead to hysterectomy in approximately 1.1–1.4 cases 
per 10000 abortions (2, 9). The increasing rate of primary 
and repeated cesarean deliveries has increased the 
incidence of abnormal placentation, including CSP, placenta 
previa, and cervical pregnancy (10). Before performing 
invasive methods such as laparoscopy, laparotomy, and 
hysterectomy, UAE is recommended because it is associated 
with less morbidity and mortality (3). Although UAE is less 
commonly used for post-abortion hemorrhage, this method 
has been successful in most published cases (6, 11, 12). 
Steinauer et al. (6) have reported that UAE is successful 
in avoiding hysterectomy in 38 (90%) of 42 patients with 
post-abortion hemorrhage. In their study, all embolization 
failures occurred in women who received histopathological 
confirmation of placenta accreta, increta, or percreta (6). In 
our study, 8 of the 29 patients had abnormal placentation. 
However, D&C after UAE resulted in no hysterectomy or 
massive bleeding, suggesting that prophylactic UAE was 
successful, even in this group of patients with high risk of 
bleeding.
Clinical trials of prophylactic UAE before D&C or during 
delivery to avoid serious complications of post-abortion 
hemorrhage in patients at high risk for bleeding have been 
reported (5, 7). Wang et al. (5) have used a prophylactic 
UAE before D&C in 128 patients with CSP. Among these 
patients, 113 showed intraoperative blood loss volume of 
< 500 mL after prophylactic UAE (5). In 10 of 15 patients 
with intraoperative blood loss volumes of > 500 mL, uterus 
was preserved, suggesting that prophylactic UAE was at 
least successful in preventing hysterectomy (5). If the 
patient still bled > 500 mL, UAE was not successful for 
preventing bleeding. In our cohort, 15 of 29 patients had 
CSP or cervical pregnancy. All of them underwent successful 
prophylactic UAE before D&C. An important advantage of 
prophylactic UAE is that it prevents blood loss during D&C 
in high-risk patients, resulting in decreased morbidity. 
D&C can sometimes result in unforeseen massive bleeding. 
However, elective prophylactic UAE may decrease the risk 
Fig. 3. Cesarean section scar pregnancy. 
A. Transvaginal ultrasonographic image showing gestational sac (arrows) in anterior wall of lower uterine body. Patient underwent cesarean 
section 5 years earlier. B. Angiogram of right internal iliac artery showing engorged uterine artery and contrast staining in lower uterine body. C. 
Fluoroscopic image after embolization showing contrast stasis due to embolized gel foam in right uterine artery.
A B C
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of this complication and preserve fertility by avoiding 
undesired hysterectomy for unsuspected bleeding during 
therapeutic abortion.
Serious complications, including labial or vaginal 
necrosis with bladder fistula and endometrial atrophy with 
permanent amenorrhea, have been reported to be related to 
UAE in several studies (13, 14). In our study series, none of 
our patients had any complications related to prophylactic 
UAE. The reason for this might be due to the fact that the 
embolic material we used was biodegradable. It could be 
more easily absorbed than its alternatives (e.g., polyvinyl 
alcohol). Gel particles begin to be absorbed gradually at 
7–10 days after UAE. Therefore, the uterine arteries might 
have recovered patency over time. In our study series, all 
women who underwent prophylactic UAE and obstetric 
procedures experienced restored menstruation, even 
though no subsequent pregnancy occurred in many of these 
patients. Hong et al. (15) have found that all patients (n = 8) 
have fully recovered menstruation after UAE, similar to the 
results of our study.
This study had several limitations. One key limitation 
was that our patients were selected for inclusion at their 
obstetricians’ clinical request, resulting in selection bias. 
Eight (27.6%) of the 29 patients who did not have vaginal 
bleeding underwent prophylactic UAE to avoid expected life-
threatening bleeding complication based on obstetrician 
guidance. Prophylactic UAE decreased bleeding risk and 
obstetricians’ concerns about the potential loss of patient’s 
life or her uterus. A prospective randomized study with a 
control group is required to confirm our results. The small 
number of patients included as our study sample could also 
be a limitation, even though our patients had relatively rare 
indications for UAE. In addition, our follow-up period and 
the data obtained were insufficient to fully evaluate the 
influence of UAE on future pregnancies.
In conclusion, prophylactic UAE before an abortive 
procedure in patients with high risk of bleeding or 
symptomatic bleeding might be a safe and effective way to 
manage or prevent serious bleeding, especially for women 
who wish to preserve their fertility. This procedure can 
decrease the morbidity, mortality, and the risk of undesired 
hysterectomy during an obstetric procedure in high-risk 
patients.
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